Osphena® improves specific vaginal tissue in just 12 weeks.4
Osphena®’s safety has been established through ten phase 2/3 trials.4
Osphena®’s Product Information
Starting January 8th, 2024, QPharmaRx portal will be the ONLY way to receive product literature & information.
To register, go to QPharmaRx.com
For assistance, call 1-888-664-8595
QPharmaRx is a multi-manufacturer drug sample & literature portal. This ordering site is intended for use by U.S. Healthcare professionals only.
What are SERMs?
Osphena® is not an estrogen; it is a SERM.3,4
See Osphena®’s mechanism of action
Common side effects may include hot flashes, vaginal discharge, muscle spasms, hyperhidrosis, night sweats, headaches and vaginal hemorrhage.
Help your patients save on their Osphena® prescription.
Offer your patients a unique treatment option that can help meet their needs and preferences.1,2,4
- Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790–1799.
- Kingsberg SA, Krychman M, Graham S, et al. The Women’s EMPOWER Survey: Identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14(3):413–424.
- Simon JA, Davis SR, Althof SE, et al. Sexual well-being after menopause: an International Menopause Society White Paper. Climacteric. 2018;21(5):415-427.
- Osphena Prescribing Information. January 2019.